Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Multiple Myeloma 232Lymphoma 46Lymphoma, Mantle-Cell 44Neoplasms, Plasma Cell 40Recurrence 30Lymphoma, Non-Hodgkin 29Lymphoma, Follicular 26Leukemia, Myeloid, Acute 25Lymphoma, Large B-Cell, Diffuse 22Waldenstrom Macroglobulinemia 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Lymphoma, B-Cell, Marginal Zone 19Leukemia, Lymphocytic, Chronic, B-Cell 19Carcinoma, Non-Small-Cell Lung 18Leukemia 15Hodgkin Disease 13Neoplasms 12Immunoglobulin Light-chain Amyloidosis 12Hematologic Neoplasms 11Unspecified Adult Solid Tumor, Protocol Specific 9Myelodysplastic Syndromes 9Lymphoma, B-Cell 9Burkitt Lymphoma 9Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, Large-Cell, Anaplastic 8Head and Neck Neoplasms 8Congenital Abnormalities 8Breast Neoplasms 8Sarcoma 7Lymphoma, Extranodal NK-T-Cell 7

Interventions

Carboplatin 7Paclitaxel 6Talc 5Docetaxel 5Bevacizumab 4Taxes 3Gemcitabine 3Cisplatin 3Trastuzumab 2High-Energy Shock Waves 2Erlotinib Hydrochloride 2Doxycycline 2Cetuximab 2Bortezomib 2viscum album peptide 1tipifarnib 1saracatinib 1romidepsin 1endostar protein 1Zoledronic Acid 1Vinorelbine 1Valacyclovir 1Tyrosine Kinase Inhibitors 1Thoracoscopy 1Thoracoscopes 1Thoracic Surgery, Video-Assisted 1Thoracentesis 1Surveys and Questionnaires 1Sorafenib 1Povidone-Iodine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Pleural Effusion, Malignant × Bortezomib × Clear all
NCT00118183 2013-06-04

Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
62 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Pleural Effusion, Malignant

NCT00052338 2013-01-23

Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Completed
34 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡